Effect of targeting treatment of mitomycin C immunoconjugate on stomach neoplasm
Chen, L.J.; Zhang, S.Y.; Zhang, J.L.; Zhang, Z.; Li, S.; Chen, M.; Zhang, X.Y.; Chen, X.T.
Zhongguo Yao Li Xue Bao 14(6): 572-576
1993
ISSN/ISBN: 0253-9756 PMID: 8010062 Document Number: 418738
An anti-gastric cancer monoclonal antibody MGb-2-mitomycin C conjugate via dextran T-70 as intermediate (MGb-2-PAD-MMC) was produced, and 28-30 g molecules of MMC were introduced into 1 g molecule of MGb-2. Ninety-six hours after ip of 125I-MGb-2-PAD-MMC (1.48 MBq/22 mu-g MGb-2 per mouse) to nude mice bearing human gastric cancer SGC-7901, the tumor tissue:blood (T/NT) radioactivity ratio was 2.6, very much higher than that of the control 125I-normal IgG-PAD-MMC group (T/NT = 0.20). Single photo computed tomography imaging confirmed the results of biodistribution study. MGb-2-PAD-MMC exhibited selective killing action on the SGC-7901 cells in vitro, which was considered to be mediated by monoclonal antibody MGb-2. Nude mice inoculated with SGC-7901 xenograft in bilateral subrenal capsule were treated by MMC (ip), human recombinant interferon-alpha (Hu-IFN-alpha im), MGb-2-PAD-MMC (ip) and MGb-2-PAD-MMC + Hu-IFN-alpha daily for 5 d beginning 4 h after inoculation. The efficacy of the reagents estimated by the reduction of tumor size and calculated by T/C (%), was 28.3%, 16.4%, 47.8%, and 83.1%, respectively. These results demonstrated that the antitumor effect of MGb-2-PAD-MMC was superior to free MMC, and that the Hu-IFN-alpha might further enhance the action of MGb-2-PAD-MMC.